Last reviewed · How we verify
Nucleotide drugs Control group
At a glance
| Generic name | Nucleotide drugs Control group |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Efficacy of Collagendep in Reducing Vulvar Dryness in Patients With Lichen Sclerosus Treated With Fat Grafting (NA)
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (PHASE3)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- ISTH/ANRS 0409s INTEGRATE Lassa Fever Study (PHASE2, PHASE3)
- Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: